Plasmid DNA CDMO demand — the Aldevron (Danaher), Thermo Fisher, Charles River, and Wacker creating GMP-grade plasmid DNA for AAV gene therapy (triple transfection), mRNA vaccines (template for in vitro transcription), lentiviral vectors (packaging), and DNA vaccines representing the most foundational supply segment in the global cell and gene therapy CDMO market — creates the most...

Market Overview The Host Cell Protein (HCP) Testing Market is rapidly growing as biotechnology, pharmaceutical manufacturing, and biologics development continue to expand globally. HCP testing is a critical quality control step used to detect and quantify residual proteins originating from host cells during the production of biologics such as monoclonal antibodies, vaccines, cell therapies,...

Market Overview The Host Cell Protein (HCP) Testing Market is rapidly growing as biotechnology, pharmaceutical manufacturing, and biologics development continue to expand globally. HCP testing is a critical quality control step used to detect and quantify residual proteins originating from host cells during the production of biologics such as monoclonal antibodies, vaccines, cell therapies,...

FBS and Therapeutic Safety: Minimizing Immune Risks Immunogenicity—the risk of triggering immune responses—is a critical concern when using Fetal Bovine Serum (FBS) in therapeutic cell cultures. Even trace bovine proteins can cause patient rejection, limiting FBS use in drug production. By 2026, innovations reducing FBS immunogenicity are making it safer for applications like...

Biologics manufacturing — the production of large molecule drugs including monoclonal antibodies, fusion proteins, antibody-drug conjugates, recombinant proteins, vaccines, cell therapies, gene therapies, and mRNA therapeutics through biological cell expression systems requiring complex upstream cell culture, downstream purification, formulation, and fill-finish operations that are...

The South Korea Dravet Syndrome market is on the cusp of transformative changes, projected to see significant growth through innovation and investment. Expected to reach a market size of 14.75 million USD by 2024, the market could expand to 39.25 million USD by 2035, reflecting an impressive CAGR of 9.3%. This upward trajectory underscores the importance of understanding current market trends,...

The competitive landscape is defined by both established diagnostic giants and agile biotech startups. A look at the current Non-Alcoholic Steatohepatitis Biomarkers Market Share shows that companies like Siemens Healthineers, Roche, and Abbott are leading the way with their integrated laboratory platforms. However, companies like GENFIT and Labcorp are gaining significant ground through the...